share_log

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $10

Benzinga ·  Oct 24, 2023 08:20

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and lowers the price target from $13 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment